GAITHERSBURG, Md., Nov. 3 /PRNewswire-FirstCall/ -- Today GenVec, Inc.
(Nasdaq: GNVC) announced that Paul H. Fischer, Ph.D., President and CEO, will
present a company overview highlighting recent developments at the Merriman
Curhan Ford's 6th Annual Investor Summit on Tuesday, November 10, 2009 at 9:20
am EST at Sofitel Hotel in New York, NY.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO )
A webcast of Dr. Fischer's presentation will be available both live and on
replay. To access either the live or archived webcast, log on to GenVec's
website at www.genvec.com, click on "Investor Relations," and proceed to
"Webcasts & Data." The replay will be available 24 hours after the live
presentation and will be accessible for 30 days.
More information about the conference can be found at: www.mcfco.com.
About GenVec
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs
and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal
clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also
been and is currently being evaluated for its potential use in the treatment
of several other cancers, including esophageal cancer, rectal cancer, and head
and neck cancer. GenVec also uses its proprietary adenovector technology to
develop vaccines for infectious diseases including HIV, malaria,
foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2.
Additional information about GenVec is available at www.genvec.com and in the
company's various filings with the Securities and Exchange Commission.
About Merriman Curhan Ford
Merriman Curhan Ford (Nasdaq: MERR) is a financial services firm focused on
fast-growing companies and the institutions that invest in them. The company
offers high-quality investment banking, equity research, institutional
services and corporate & venture services, and specializes in five growth
industry sectors: CleanTech, Consumer, Media & Internet, Health Care, Natural
Resources and Technology. For more information, please go to www.mcfco.com.
Investor Contact: Media Contact:
GenVec, Inc. Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro Andrew Mielach
(301) 944-1877 (212) 827-0020
ddipirro@genvec.com amielach@tiberendstrategicadvisors.com
SOURCE GenVec, Inc.
Investors, Danielle M. DiPirro of GenVec, Inc., +1-301-944-1877,
ddipirro@genvec.com; or Media, Andrew Mielach of Tiberend Strategic Advisors,
Inc., +1-212-827-0020, amielach@tiberendstrategicadvisors.com
